Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression

1

Empagliflozin improves cardiac function in obese diabetic mice with HFpEF, showing benefits beyond glycemic control.
2

The drug enhances diastolic function and may reduce arrhythmias in type 2 diabetes patients with or without HFpEF.
3

Empagliflozin regulates ionic movements and excitation-contraction coupling in cardiomyocytes, impacting heart function.
4

Chronic empagliflozin treatment restores cardiomyocyte electrophysiology and attenuates proarrhythmia in HFpEF models.
5

The study utilized a two-hit cardiometabolic HFpEF mouse model to evaluate the long-term effects of empagliflozin.

Basic Research In Cardiology

by Juliana Mira Hernandez, Logan R. J. Bailey, Victoria R. Salemme, Christopher Y. Ko, Erin Y. Shen, Megan Ngim, Duong T. Hoang, Melissa Corea, Julie Bossuyt, Jennifer M. Davis, Donald M. Bers, Bence Hegyi
May 21, 2026

1